<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617028</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK016</org_study_id>
    <nct_id>NCT04617028</nct_id>
  </id_info>
  <brief_title>Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis</brief_title>
  <official_title>A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants&#xD;
      with Intermediate-2 or High-risk myelofibrosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Splenic response rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Splenic response rate at Week 24 is defined as the proportion of participants achieving a ≥ 35% reduction in spleen volume at Week 24 from baseline as measured by MRI or CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of transfusion dependent patients converted to non-transfusion dependent patients at baseline</measure>
    <time_frame>From start of drug administration up to 7 days after last dose of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Jaktinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxycarbamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib</intervention_name>
    <description>Jaktinib Hydrochloride Tablets administered orally twice daily</description>
    <arm_group_label>Jaktinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match Hydroxycarbamide</intervention_name>
    <description>Placebo to match Hydroxycarbamide Tablets administered orally twice daily</description>
    <arm_group_label>Jaktinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxycarbamide Tablets</intervention_name>
    <description>Hydroxycarbamide Tablets administered orally twice daily</description>
    <arm_group_label>Hydroxycarbamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match Jaktinib</intervention_name>
    <description>Placebo to match Jaktinib Tablets administered orally twice daily</description>
    <arm_group_label>Hydroxycarbamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old,either male or female;&#xD;
&#xD;
          -  Subjects diagnosed with a PMF according to World Health Organiztion criteria (2016&#xD;
             Edition), or patients diagnosed with a Post-PV-MF or Post-EF-MF according to&#xD;
             International Working Group for Myeloproliferative Neoplasms Research and Treatment&#xD;
             criteria;&#xD;
&#xD;
          -  High risk or intermediate-2 risk as defined by the Dynamic International Prognostic&#xD;
             Scoring System (DIPSS) for Primary Myelofibrosis;&#xD;
&#xD;
          -  Subjects have no plan for stem cell transplantation in the near future;&#xD;
&#xD;
          -  Life expectancy of &gt; 24 weeks;&#xD;
&#xD;
          -  ECOG performance status of 0-1;&#xD;
&#xD;
          -  Palpable splenomegaly at least 5 cm below left costal margin;&#xD;
&#xD;
          -  Peripheral blood blast count ≤ 10%;&#xD;
&#xD;
          -  Subjects who have not yet received treatment with a JAK inhibitor, or Subjects who&#xD;
             have been treated with JAK inhibitors for ≤10 days;&#xD;
&#xD;
          -  Subjects have not received growth factor, thrombopoietin mimetics or platelet&#xD;
             transfusion(s) within 2 weeks before the randomization; ANC≥ 1.0×10^9/L, platelet&#xD;
             count ≥ 100×10^9/L within 2 days before the randomization;&#xD;
&#xD;
          -  Normal functions in major organs within 7 days before the randomization, fulfilling&#xD;
             the following criteria: ALT and AST ≤ 2.5×ULN; DBIL and TBIL ≤ 2.0×ULN; serum&#xD;
             creatinine ≤ 1.5×ULN;&#xD;
&#xD;
          -  If the subject is receiving any anti-myelofibrosis treatment (except for JAK&#xD;
             inhibitors and hydroxyurea) at screening, the dosing regimen must remain unchanged for&#xD;
             at least 2 weeks before screening. If the investigator judges that there is no need to&#xD;
             continue to use, stop the use of thalidomide, androgens and prednisone&gt; 10 mg during&#xD;
             screening. The drugs used to improve anemia should be stopped for at least 6&#xD;
             half-lives or 2 weeks before randomization(whichever is the longer);&#xD;
&#xD;
          -  If the subject is receiving Hydroxycarbamide treatment at screening, the drug must be&#xD;
             discontinued ≥ 2 weeks before the randomization;&#xD;
&#xD;
          -  Meet the requirements of the ethics committee and willing to sign the informed consent&#xD;
             form;&#xD;
&#xD;
          -  Ability to comply with trial and follow-up procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any significant clinical and laboratory abnormalities which may affect&#xD;
             the safety evaluation, such as uncontrolled diabetes, uncontrolled hypertension after&#xD;
             taking two or more hypotensive drugs, peripheral neuropathy;&#xD;
&#xD;
          -  Subjects with congestive heart failure, uncontrolled or unstable angina or myocardial&#xD;
             infarction, cerebrovascular accident, or pulmonary embolism within 24 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Subjects who have not fully recovered from surgical operation within 4 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Subjects suffering from arrhythmia and requiring treatment at screening;&#xD;
&#xD;
          -  Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal&#xD;
             infections requiring treatment at screening;&#xD;
&#xD;
          -  Chest X-rays suggest an active lung infection at screening;&#xD;
&#xD;
          -  Subjects who had active tuberculosis infection within 48 weeks before&#xD;
             screening;γ-Interferon release test suggests latent tuberculosis infection at&#xD;
             screening;&#xD;
&#xD;
          -  Subjects who had undergone splenectomy, or received radiotherapy to the spleen within&#xD;
             48 weeks before screening;&#xD;
&#xD;
          -  Subjects with known human immunodeficiency virus (HIV), known active infectious&#xD;
             Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC);&#xD;
&#xD;
          -  Subjects with epilepsy or patients who have received psychotropic drug or sedatives&#xD;
             during screening;&#xD;
&#xD;
          -  Female subjects who are pregnant, currently breastfeeding, planning to become&#xD;
             pregnant;Subjects who are unable to adopt effective contraceptive methods during the&#xD;
             study; Male subjects who did not use condoms during the dosing period and within 2&#xD;
             days after the last dose&#xD;
&#xD;
          -  Subjects who had experienced malignant tumors within the past 5 years (except for&#xD;
             adequately treated local basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ that have been cured);&#xD;
&#xD;
          -  Subjects who are unsuitable to the trial in combination with other serious diseases,&#xD;
             as identified by the investigator;&#xD;
&#xD;
          -  Subjects with suspected allergies to Jaktinib or its excipient;&#xD;
&#xD;
          -  Subjects who have participated in another clinical trial of a new drug or medical&#xD;
             instrument within 12 weeks before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, PhD</last_name>
    <phone>+86-0571-87236896</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, PhD</last_name>
      <phone>13505716779</phone>
      <email>jiej0503@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

